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Background: Recent research has reported that patients receiving bolus (frequent large doses to achieve iron
repletion) versus maintenance dosing of iron have an increased short-term risk of infection, but a similar risk of
cardiovascular events. We sought to determine whether these findings could be replicated using the same methods
and a different data source.
Methods: Clinical data from 6,605 patients of a small U.S. dialysis provider merged with Medicare claims data were
examined. Iron dosing patterns (bolus, maintenance, no iron) were identified during 1-month exposure periods and
cardiovascular and infection-related outcomes were assessed during 3-month follow-up periods. The effects of
bolus versus maintenance dosing were assessed using Cox proportional hazards regression analyses to estimate
hazard ratios and semiparametric additive risk models to estimate hazard rate differences, controlling for
demographic and clinical characteristics, laboratory values and medications, and comorbidities.
Results: 48,050 exposure/follow-up periods were examined. 13.9 percent of the exposure periods were bolus
dosing, 49.3 percent were maintenance dosing, and the remainder were no iron use. All of the adjusted hazard
ratios were >1.00 for the infection-related outcomes, suggesting that bolus dosing increases the risk of these events.
The effects were greatest for hospitalized for infection of any major organ system (hazard ratio 1.13 (1.03, 1.24)) and
use of intravenous antibiotics (hazard ratio 1.08 (1.02, 1.15). When examining the subgroup of individuals with
catheters, the hazard ratios for the infection-related outcomes were generally greater than in the overall sample.
There was little association between type of dosing practice and cardiovascular outcomes.
Conclusions: Results of this study provide further evidence of the association between bolus dosing and increased
infection risk, particularly in the subgroup of patients with a catheter, and of the lack of an association between
dosing practices and cardiovascular outcomes.
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Intravenous iron is used in combination with erythropoiesis-
stimulating agents (ESAs) to treat the anemia of
hemodialysis patients. Recent studies have reported a
beneficial effect of iron dosing on anemia parameters
in hemodialysis patients [1-4]. While the safety of
ESAs in chronic kidney disease has been examined in
clinical trials [5-7], less is known about the safety of* Correspondence: janet_freburger@unc.edu
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unless otherwise stated.intravenous iron. Several biological mechanisms sug-
gest that sub-optimal use of iron could lead to adverse
clinical events [8]. Frequent administration of iron may
lead to oversaturation of transferrin and the release of
free, catalytically active iron into the plasma [9]. Be-
cause iron is essential for bacterial growth, free iron in
circulation may increase the risk of infection [10,11].
Indeed, frequency of iron administration has been
found to be associated with increased risk of infection-
related mortality in ESRD [12]. Free iron is also known
to catalyze the formation of highly reactive oxygen species
[13,14]. These could give rise to lipid radicals, which mayral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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increasing the risk of cardiovascular events [8,17].
A recently completed a large-scale observational study
examined the short-term comparative safety of intraven-
ous iron dosing strategies in hemodialysis patients and
found that patients receiving bolus (frequent large doses
to achieve iron repletion) versus maintenance dosing
had higher risks of infection-related hospitalization and
infection-related death, and that these risks were greatest
among the subgroup of patients with a dialysis catheter
[18]. No association was found between large-dose intra-
venous iron treatment strategies and cardiovascular mor-
bidity and mortality [19]. The study was conducted using
data from a large U.S. dialysis chain merged with data from
the United States Renal Data System (USRDS). Because the
previous study was the first large epidemiologic study to
address risks of adverse events associated with intravenous
iron use, we sought to determine whether these findings
could be replicated using the same methods with data from
another U.S. dialysis chain where the patient demographics,
case mix, and other aspects of medical practice may differ.
Specifically, we examined short-term infection and cardio-
vascular risk associated with bolus versus maintenance




Data for this study came from the clinical database of a
small U.S. dialysis organization and the United States
Renal Data System (USRDS), a national data system that
collects, analyzes and distributes information about
the treatment of ESRD. The clinical database contains
information on approximately 6,000 dialysis patients
per year from approximately 60 dialysis facilities, pri-
marily located in the Northeast and Midwest. Clinical,
laboratory, and treatment data are captured using
standardized electronic data entry. We used the clin-
ical database to obtain detailed information on iron
dosing, epoetin alfa (EPO) dosing, clinical laboratory
values (e.g., hemoglobin, transferrin saturation [TSAT],
serum ferritin), and current vascular access. These data
were merged with data from the following USRDS files:
the Medical Evidence Report Form, the Medicare
Enrollment files, and the standard analytic files, which
contain final action Medicare claims [20]. Data ex-
tracted from the USRDS files included demographic,
health care use (e.g., hospitalizations, outpatient care),
comorbidity, and clinical (e.g., vintage) information.
Both the clinical data and USRDS data were purchased
by the study team and were governed by Data Use
Agreements with the Renal Research Institute and the
USRDS, respectively. These data are not freely avail-
able to other researchers.Study design
We utilized a retrospective cohort design with a 6-month
baseline period, a one-month iron and EPO exposure
period, and a three-month follow-up period. The index date
of the exposure period was anchored on a TSAT lab as this
information is used to guide iron administration. While
serum ferritin labs may also guide iron administration, we
focused on TSAT labs only because these were, on aver-
age, measured monthly in our data, whereas serum ferritin
labs occurred less frequently (every 2–3 months on aver-
age). The exposure period began the day after the qualify-
ing TSAT measurement.
Cohort identification
We first identified center-based hemodialysis patients
who had at least one TSAT measurement after undergo-
ing dialysis for at least 9 months. The 9-month period
accounted for the 6-month baseline period and an add-
itional 3 months from dialysis initiation to allow for
stability in the CMS claims processing [20]. Individuals
with polycystic kidney disease were then excluded as
the anemia management of these patients differs
greatly from that of most ESRD patients receiving
hemodialysis. Eligible patients could contribute more
than one TSAT measurement. TSAT measurements
were eligible if they occurred between January 30, 2006
(to allow assessment of lab values and medications in
the last month of baseline) and November 30, 2010
(to allow for the 1-month exposure period and at least
one day of follow-up).
Measurements of TSAT were excluded if 1) both ferric
gluconate and iron sucrose were administered during the
exposure period; 2) there was an insufficient duration of
Part A claims at baseline (i.e., <120 days of Part A claims),
suggesting incomplete data; or 3) there were fewer than 9
dialysis sessions in the last month of baseline or during
the exposure period. We also excluded TSAT records
with missing covariate information and TSAT measure-
ments that occurred in the follow-up period of a prior
eligible TSAT (Figure 1).
Study variables
Exposures
The primary iron exposures of interest were bolus versus
maintenance iron dosing. We also created a no iron
category for individuals who received no iron during
the one month exposure period. A month was classified
as a bolus month if, during that month, two consecutive
iron doses of at least 100 mg were administered and
the total iron dose had the potential to exceed 600 mg
within 30 days based on spacing between the doses
in the sequence. For example, two consecutive iron
doses of 200 mg each, within 10 days, would qualify
as a bolus dose according to our definition. Months
Figure 1 Cohort creation.
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“maintenance months”.
Outcomes
We examined eight adverse clinical outcomes: death
from any cause; hospitalized for pneumonia, vascular access
infection, or sepsis; hospitalized for infection of any major
organ system; use of intravenous antibiotics; hospitalized
for myocardial infarction (MI), hospitalized for stroke, and
cardiovascular disease-related death. We also created three
composite outcomes: hospitalized for pneumonia, vascular
access infection, or sepsis or infection-related death
(a more specific infection-related composite outcome);
hospitalized for any infection or use of intravenous antibi-
otics (a more sensitive infection-related composite outcome);
and cardiovascular hospitalization or cardiovascular-relateddeath. Outcomes were determined by examining the
Medicare death notification and Medicare inpatient and
outpatient claims. The specific codes used to define our
outcomes are presented in an additional online file
(Additional file 1: Table S1).
Covariates
We included several covariates in our analyses
(Additional file 1: Table S2) to control for potential
confounding. The choice of these variables was based on
content expertise of the study team, previous literature, and
data availability and included demographic characteris-
tics, clinical characteristics (e.g., vintage, BMI, type of
vascular access), laboratory and anemia management
variables (e.g., baseline hemoglobin, ferritin, TSAT, concur-
rent EPO dose), and hospital days. We also included several
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vascular events), based on the Elixhauser classification [21]
and content expertise of the investigative team.
Statistical analyses
To assess the relation between iron dosing practices and
adverse outcomes, we used Cox proportional hazards
regression analyses to estimate hazard ratios and semi-
parametric additive risk models [22] to estimate hazard
rate differences. Additive models estimate the absolute
difference in event rate per unit change in the exposure
variable, whereas Cox models provide estimates of rela-
tive hazard on a multiplicative scale [22]. From a clinical
and public health perspective, the absolute difference
may be the more useful estimate because it provides in-
formation about the number of harmful or beneficial
events for a given unit of change in the exposure over a
given period of time. To account for the within-patient
correlation of the repeated measures, we used the robust
sandwich covariance estimate [23] for the Cox models
and a cluster bootstrap estimation for the additive risk
models. We addressed potential confounding by control-
ling for the covariates described above. Individuals were
censored by death (for the hospitalization outcome), loss
to follow-up, kidney transplant, or administratively by
the end of available data. We conducted analyses on the
entire sample and, based on results of the previous study
where effects were greatest in the catheter subgroup [18],
examined the infection-related outcomes in the subset of
individuals who used a catheter. We did not conduct any
further subgroup analyses because there was no evidence of
other subgroup effects/effect modification in the previous
study and due to sample size limitations.
Sensitivity analyses
We assessed the sensitivity of our results to the addition
of other potentially relevant covariates (Additional file 1:
Table S2) and to changes in the length of the exposure/
follow-up periods: 1 month/6 weeks, 2 weeks/6 weeks,
and 1 week/6 weeks (Additional file 1: Table S3). We also
conducted a sensitivity analysis using a propensity score
approach with inverse probability of treatment weights
[24]. We used logit models to predict the iron categories
(bolus, maintenance) among those who received iron.
For each observation, we then estimated the probability of
receiving the treatment actually received and took the
reciprocal of this value to create the inverse-probability-
of-treatment weights. The weights were then stabilized
[24] and used in the Cox models for the full sample and
the catheter subgroup using the 1 month exposure/
3 month follow-up study design.
This study was reviewed and approved by the Institutional
Review Board (Public Health-Nursing) at the University of
North Carolina, Chapel Hill, NC (Study #10-1674) and wasexempt from requiring patient consent. While the IRB
reviewed the DUAs for the data used in this study, it did
not have any direct influence on data accession.
Results
6,605 patients met study entry requirements and contrib-
uted data on 48,050 exposure/follow-up periods (Figure 1).
Sample characteristics are presented in Table 1, stratified
by iron exposure group. Relative to the earlier study [18],
the sample for this study had a greater proportion of Blacks
and residents of the Northeast. Patients in this study
were also on dialysis longer, had less catheter use, a higher
proportion of comorbidities, and higher rates of infection
at baseline. Demographic and clinical characteristics were
generally similar among the dosing groups. Catheter use
was highest in the bolus dosing group and lowest in the
no iron group. TSAT and ferritin values were lowest in the
bolus group and highest in the no iron group, as might be
expected. The prevalence of comorbidities was generally
highest in the bolus dosing group and lowest in the no
iron group.
Table 2 presents the adjusted hazard ratios and rate
differences for the comparison of bolus versus maintenance
dosing for the entire sample. These findings are graphically
represented in Figure 2. All of the adjusted hazard ratios
were >1.00 for the infection-related outcomes, though the
95% confidence intervals included 1.00 for three of the six
hazard ratios. The effects were greatest for hospitalized for
infection of any major organ system (HR: 1.13) and use of
intravenous antibiotics (HR: 1.08) and indicate that bolus
dosing increases the risk of these events. On the additive
scale, individuals who received bolus dosing had 59 more
hospitalizations for major organ system infection, per 1000
person-years, than individuals who received maintenance
dosing. Use of intravenous antibiotics was also higher
among individuals who received bolus versus maintenance
dosing (72 more events per 1000 person-years).
The adjusted hazard ratios for all-cause death and
cardiovascular outcomes were relatively imprecise, with
confidence intervals including the null. Relative to the
rate differences for the infection outcomes, the rate dif-
ferences for all-cause death and the cardiovascular out-
comes were much closer to the null, though there was a
slight suggestion of a protective effect on cardiovascular
death (Table 2 and Figure 2). Our results were robust to
variations in the length of the exposure and follow-up
periods (Additional file 1: Table S3) and the addition of
covariates beyond our a priori specified multivariable
models (Additional file 1: Table S4).
The adjusted hazard ratios and rate differences for the
infection-related outcomes in the catheter subgroup are
presented in Table 3 with graphic representation in Figure 3.
The effect measures all indicated increased risk, but were
imprecise, with wide 95 percent confidence intervals that
Table 1 Demographics and clinical characteristics of sample, stratified by iron dosing (N=48,050)
Characteristics, mean (SD) or% Bolus (13.9%) Maintenance (49.3%) Non-user (36.8%)
Demographic
Age, y 60.1 (15.3) 61.4 (15.1) 61.4 (15.1)
Female 45.8 45.1 45.3
Race: White 38.2 40.1 37.3
Black 56.7 54.1 56.8
Other 5.1 5.7 5.9
Region: Midwest 6.2 11.0 8.1
Northeast 80.6 84.3 78.6
South 10.6 2.8 9.6
West 1.8 1.4 3.0
Clinical
Vintage, y 4.8 (4.7) 5.1 (5.0) 5.8 (5.5)
Body Mass Index 32.8 (23.5) 33.9 (29.8) 31.6 (24.7)
Catheter Use 21.6 19.5 17.2
Laboratory and Anemia Management Variables
Albumin at baseline 3.84 (0.41) 3.91 (0.37) 3.93 (0.38)
Hemoglobin at baseline 11.5 (1.4) 12.0 (1.3) 11.9 (1.4)
Index TSAT 23.7 (9.5) 31.4 (10.9) 35.8 (14.3)
Ferritin at baseline 625 (479) 745 (536) 862 (588)
Iron (mg) at baseline 314 (316) 279 (214) 109 (241)
Iron (mg) during exposure 700 (291) 227 (118) 0.0 (0.0)
EPO at baseline (1000U) 111 (98) 75.3 (78.3) 62.0 (74.0)
EPO during exposure (1000U) 113 (100) 73.1 (77.0) 63.0 (73.9)
Comorbidities
Hospital days in last month 1.0 (2.3) 0.6 (1.9) 0.5 (1.8)
Infection in last month 17.5 12.6 10.4
Infection in last 6 mos. Pneumonia 16.7 12.8 11.5
Sepsis 23.5 19.0 14.9
Vascular access 15.0 10.1 9.2
Diabetes 67.5 64.1 60.7
Ischemic stroke 16.7 12.9 12.5
Myocardial Infarction 6.2 4.4 4.0
COPD, Asthma 24.4 20.0 18.0
Cancer 12.1 10.9 11.7
GI bleeding 9.5 6.1 5.2
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statistical significance, with the lower limit of the con-
fidence interval 0.98 or 0.99.
Results of our analyses using IPTWs are presented in
Additional file 1: Table S5 and Additional file 1: Table S6.
The IPTWs balanced the sample characteristics for
the bolus and maintenance groups with absolute stan-
dardized differences ranging from 0 – 0.15 with all
differences < =0.05 with the exception of baseline iron
which was 0.15. (Additional file 1: Table S5). Thesefindings indicate that the weighting was successful in
balancing the bolus and maintenance groups on baseline
characteristics. The mean of the stabilized weights was
1.00, as expected [25], and there were no extremely small
or large weights (0.25 – 9.1). A comparison of the results
of the multivariable and IPTW-adjusted analyses is pre-
sented in Additional file 1: Table S6. For the full sample,
there was little difference in the multivariate adjusted and
IPTW adjusted results, particularly in regard to the in-
fection outcomes. For the catheter subgroup, the point
Table 2 Multivariable adjusted associations between bolus versus maintenance (Referent) dosing and study
outcome (N=48,050)
Outcome Effect measure1 Estimate (95% CI)
Death from any cause Hazard Ratio 0.92 (0.79, 1.06)
Rate Difference -16 (-42, 13)
Infection Outcomes
Hospitalized for pneumonia, sepsis, vascular access infection Hazard Ratio 1.08 (0.96, 1.21)
Rate Difference 21 (-9.2, 54)
Hospitalized for infection of any major organ system Hazard Ratio 1.13 (1.03, 1.24)
Rate Difference 59 (19, 106)
Use of intravenous antibiotics Hazard Ratio 1.08 (1.02, 1.15)
Rate Difference 72 (9.1, 135)
Infection-Related Death Hazard Ratio 1.17 (0.80, 1.71)
Rate Difference 3.9 (-5.1, 14)
Hospitalized for pneumonia, vascular access infection, sepsis or infection-related death Hazard Ratio 1.08 (0.96, 1.21)
Rate Difference 23 (-9.5, 56)
Hospitalized for any infection or use of intravenous antibiotics Hazard Ratio 1.08 (1.02, 1.15)
Rate Difference 107 (28, 187)
Cardiovascular Outcomes
Hospitalized for stroke Hazard Ratio 1.07 (0.77, 1.47)
Rate Difference 1.7 (-10, 15)
Hospitalized for Myocardial Infarction Hazard Ratio 0.95 (0.69, 1.32)
Rate Difference -1.7 (-13, 10)
Cardiovascular-related death Hazard Ratio 0.82 (0.66, 1.02)
Rate Difference -14 (-31, 0.97)
Cardiovascular-related hospitalization or death Hazard Ratio 0.92 (0.78, 1.09)
Rate Difference -11 (-35, 13)
1Rate difference per 1000 patient years.
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relative to the full sample, and were much less precise.
In most cases the point estimates were in the same dir-
ection for both analyses.
Discussion
Consistent with previous work [18,19], we found evi-
dence of an association between bolus dosing and infec-
tion outcomes and no association between bolus dosing
and cardiovascular outcomes, in a sample of patientsFigure 2 Forest plot of study outcomes for the entire sample (N=48,0
differences between bolus versus maintenance (referent) dosing and studyreceiving center-based hemodialysis. Patients receiving
bolus versus maintenance dosing were more likely to
have infection-related events, with the most notable
rate differences for use of intravenous antibiotics and
hospitalization for any infection. While some of the
hazard ratios for the infection outcomes had confidence
intervals that included the null, all of these hazard ratios
were >1.00 (HR’s ranging from 1.08-1.17) and similar in
magnitude to the hazard ratios in the previous study exam-
ining infection risks [18] (HR’s ranging from 1.05-1.11). All50). Forest plot of multivariable adjusted hazard ratios and rate
outcomes for the entire sample.
Table 3 Multivariable adjusted associations between bolus versus maintenance (Referent) dosing and infection-related
outcomes for the catheter subgroup (N=9,113)
Outcome Effect measure1 Estimate (95% CI)
Hospitalized for pneumonia, sepsis, vascular access infection Hazard Ratio 1.19 (0.99, 1.44)
Rate Difference 100 (-10, 201)
Hospitalized for infection of any major organ system Hazard Ratio 1.15 (0.98, 1.35)
Rate Difference 106 (-19, 223)
Use of intravenous antibiotics Hazard Ratio 1.08 (0.96, 1.22)
Rate Difference 126 (-36, 332)
Infection-Related Death Hazard Ratio 1.39 (0.74, 2.61)
Rate Difference 11 (-17, 47)
Hospitalized for pneumonia, vascular access infection, sepsis or infection-related death Hazard Ratio 1.20 (0.99, 1.44)
Rate Difference 105 (-1.5, 213)
Hospitalized for any infection or use of intravenous antibiotics Hazard Ratio 1.07 (0.97, 1.19)
Rate Difference 179 (-45, 431)
1Rate difference per 1000 patient years.
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cluded the null, with one greater than 1.00 and the others
less than 1.00. These hazard ratios ranged from 0.82-1.07,
similar to those in the previous study examining cardiovas-
cular risks [19] (HR’s ranging from 0.98-1.05).
The effect measures for the catheter subgroup (Table 3)
were imprecise due to small sample size, but the magnitude
of the rate differences suggests that this group, in particular,
may be at greater risk of infection-related outcomes with
bolus versus maintenance dosing. Of particular note are
the rate differences for hospitalization for pneumonia,
sepsis, or vascular access infection and the combination
of these outcomes with infection-related death. Patients
with a catheter who received bolus dosing experienced
approximately 100 more events per 1000 person-years
for these outcomes relative to patients with a catheter
who received maintenance dosing. These findings also
agree with the earlier study, which reported rate differences
of approximately 75 more infection-related events per 1000
person-years when comparing bolus versus maintenance
dosing in this subgroup [18].
Using the identical epidemiologic design and statistical
methods as in the previous research, we examined the
comparative short-term safety of bolus versus main-
tenance dosing using data on a different sample of U.S.
center-based hemodialysis patients. While the sampleFigure 3 Forest plot of infection-related outcomes for the catheter su
between bolus versus maintenance (referent) dosing and infection-relatedfor this analysis was much smaller (N = 48,050) than in the
previous study (N = 776,203), our findings were remarkably
similar. The characteristics of the two cohorts were similar
in some respects, but differed in regard to some demo-
graphic and clinical characteristics. Also, a majority of pa-
tients in the current study were from the Northeastern
part of the U.S., while most patients in the previous study
resided in the South. The proportion of individuals that
received bolus versus maintenance dosing in the two stud-
ies were remarkably similar (13.9% received bolus dosing
in this study vs 12.6% and 49.3% received maintenance
dosing vs 49.2%). While not particularly innovative,
replicating studies provide important scientific information
that may add to a body of evidence or call into question
previous findings. Our study has several limitations, includ-
ing its non-experimental design, its focus on short-term
events only, and the potential for unmeasured confounding.
We did examine our results with the addition of more
covariates and found little change in the effect measures
(Additional file 1: Table S3), suggesting that we adequately
controlled for confounding due to measured covariates.
Another limitation is that our study design required sur-
vival for at least 9 months following the start of dialysis,
which limits the generalizability of our findings to inci-
dent hemodialysis patients. We also did not validate the
categorization of our exposure variable against a goldbgroup (N=9,113). Forest plot of multivariable adjusted associations
outcomes for the catheter subgroup.
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of iron dosing and used clinical expertise to arrive at
our method of categorization.
Strengths of our study include the sound design, in which
baseline covariates were identified before the exposure
period and outcomes were ascertained after the exposure
period, and our rich data base, which contained clinical
data merged with administrative health care claims data.
Building on earlier analyses, the results of this study provide
further evidence of the potential risks of bolus dosing of
intravenous iron. These risks should be considered in light
of the reported benefits of bolus dosing, which include
diminished ESA requirements and improved anemia
management [1-4].
Conclusions
We examined the short-term comparative safety of bolus
versus maintenance dosing in a sample of center-based
hemodialysis patients and found that bolus dosing was
associated with increased infection risk, particularly in
the subgroup of patients with a catheter. We found no
association between dosing practices and cardiovascular
outcomes.
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